title: Effect of soluble ICAM-1 on a Sjögren's syndrome-like phenotype in NOD mice is disease stage dependent.
abstract: BACKGROUND
  Intercellular adhesion molecule-1 (ICAM-1) is involved in migration and co-stimulation of T and B cells. Membrane bound ICAM-1 is over expressed in the salivary glands (SG) of Sjögren's syndrome (SS) patients and has therefore been proposed as a potential therapeutic target. To test the utility of ICAM-1 as a therapeutic target, we used local gene therapy in Non Obese Diabetic (NOD) mice to express soluble (s)ICAM-1 to compete with membrane bound ICAM-1 for binding with its receptor. Therapy was given prior to and just after the influx of immune cells into the SG.
  
  
  METHODS
  A recombinant serotype 2 adeno associated virus (rAAV2) encoding ICAM-1/Fc was constructed and its efficacy tested in the female NOD mice after retrograde instillation in SG at eight (early treatment) and ten (late treatment) weeks of age. SG inflammation was evaluated by focus score and immunohistochemical quantification of infiltrating cell types. Serum and SG tissue were analyzed for immunoglobulins (Ig).
  
  
  RESULTS
  Early treatment with ICAM-1/Fc resulted in decreased average number of inflammatory foci without changes in T and B cell composition. In contrast, late treated mice did not show any change in focus scores, but immunohistochemical staining showed an increase in the overall number of CD4+ and CD8+ T cells. Moreover, early treated mice showed decreased IgM within the SGs, whereas late treated mice had increased IgM levels, and on average higher IgG and IgA.
  
  
  CONCLUSIONS
  Blocking the ICAM-1/LFA-1 interaction with sICAM-1/Fc may result in worsening of a SS like phenotype when infiltrates have already formed within the SG. As a treatment for human SS, caution should be taken targeting the ICAM-1 axis since most patients are diagnosed when inflammation is clearly present within the SG.
authors: Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors: Nienke
authors: N
authors: Roescher
authors: Jelle L
authors: JL
authors: Vosters
authors: Hongen
authors: H
authors: Yin
authors: Gabor G
authors: GG
authors: Illei
authors: Paul P
authors: PP
authors: Tak
authors: John A
authors: JA
authors: Chiorini
references: J Rheumatol. 2009 May;36(5):989-96
references: 19332626
references: J Clin Lab Immunol. 1992 Jan;37(1):39-49
references: 1339235
references: Semin Arthritis Rheum. 2008 Apr;37(5):273-92
references: 17714766
references: J Rheumatol. 2002 Sep;29(9):1884-96
references: 12233883
references: Clin Immunol Immunopathol. 1994 Aug;72(2):162-5
references: 8050187
references: Hum Gene Ther. 2003 Nov 20;14(17):1605-18
references: 14633403
references: Peptides. 2003 Mar;24(3):487-501
references: 12732350
references: Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3053-8
references: 14978265
references: J Cell Physiol. 1994 Nov;161(2):217-26
references: 7962105
references: Eur J Immunol. 1999 Jan;29(1):45-53
references: 9933085
references: Diabetologia. 1998 Nov;41(11):1298-303
references: 9833936
references: Arthritis Rheum. 2002 May;46(5):1390-8
references: 12115247
references: J Immunol. 2002 Apr 1;168(7):3641-8
references: 11907130
references: Ann Rheum Dis. 2003 Nov;62(11):1038-46
references: 14583564
references: J Rheumatol. 2005 Jun;32(6):1063-70
references: 15940769
references: Am J Pathol. 2001 Aug;159(2):671-81
references: 11485925
references: Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2770-5
references: 16477017
references: Hum Gene Ther. 2002 Jan 20;13(2):287-98
references: 11812284
references: J Virol. 2001 Aug;75(15):6884-93
references: 11435568
references: J Exp Med. 1994 May 1;179(5):1417-27
references: 7513009
references: Clin Exp Immunol. 2001 Apr;124(1):126-33
references: 11359451
references: PLoS One. 2010 Nov 15;5(11):e15478
references: 21085578
references: J Immunol. 1994 Jun 15;152(12):5969-78
references: 8207221
references: Arthritis Res Ther. 2005;7(4):R862-7
references: 15987488